Skip to main content

pd-l1-ihc-28-8-pharmdx-uc-interpretation

More personalized cancer results. One test makes it possible.

To assess the PD-L1 expression level in patient slides stained with PD-L1 IHC 28-8 pharmDx, pathologists should determine the percentage of viable tumor cells exhibiting partial linear or complete circumferential plasma membrane staining at any staining intensity.

Interpretation Manual

Download the UC interpretation manual

Contact us for a hard copy of the interpretation manual.

References

  1. PD-L1 IHC 28-8 pharmDx Instructions for Use

Want to hear more about PD-L1 IHC 28-8 pharmDx?

Contact your local sales representative

CONTACT US

Intended Use

For in vitro diagnostic use

PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), and melanoma tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity. Tumor PD-L1 status is defined by indication specific staining interpretation.